KR20200120550A - Composition for improving, preventing or treating skin disease comprising pressed juice of Echinacea purpurea - Google Patents
Composition for improving, preventing or treating skin disease comprising pressed juice of Echinacea purpurea Download PDFInfo
- Publication number
- KR20200120550A KR20200120550A KR1020200044163A KR20200044163A KR20200120550A KR 20200120550 A KR20200120550 A KR 20200120550A KR 1020200044163 A KR1020200044163 A KR 1020200044163A KR 20200044163 A KR20200044163 A KR 20200044163A KR 20200120550 A KR20200120550 A KR 20200120550A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- allergic
- inflammatory skin
- skin diseases
- juice
- Prior art date
Links
- 235000011389 fruit/vegetable juice Nutrition 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 208000017520 skin disease Diseases 0.000 title claims description 6
- 235000014134 echinacea Nutrition 0.000 title abstract description 6
- 240000004530 Echinacea purpurea Species 0.000 title abstract description 5
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 71
- 230000000172 allergic effect Effects 0.000 claims abstract description 55
- 208000026935 allergic disease Diseases 0.000 claims abstract description 53
- 235000013305 food Nutrition 0.000 claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 33
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 54
- 201000008937 atopic dermatitis Diseases 0.000 claims description 54
- 239000000284 extract Substances 0.000 claims description 33
- 239000004480 active ingredient Substances 0.000 claims description 30
- 230000036541 health Effects 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 23
- 238000009472 formulation Methods 0.000 claims description 20
- 235000013376 functional food Nutrition 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 239000008274 jelly Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- -1 troche Substances 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 206010046750 Urticaria papular Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 201000011486 lichen planus Diseases 0.000 claims description 3
- 208000008664 papular urticaria Diseases 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 241001122767 Theaceae Species 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 abstract description 17
- 238000010171 animal model Methods 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 210000000265 leukocyte Anatomy 0.000 abstract description 9
- 210000000440 neutrophil Anatomy 0.000 abstract description 8
- 206010030113 Oedema Diseases 0.000 abstract description 4
- 238000009534 blood test Methods 0.000 abstract description 3
- 210000005069 ears Anatomy 0.000 abstract 1
- 239000013642 negative control Substances 0.000 description 23
- 239000013641 positive control Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 14
- 229960003957 dexamethasone Drugs 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- 239000010978 jasper Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 235000013373 food additive Nutrition 0.000 description 8
- 239000002778 food additive Substances 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 206010003645 Atopy Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 210000003651 basophil Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000000521 hyperimmunizing effect Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940112971 protopic Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000809 air pollutant Substances 0.000 description 2
- 231100001243 air pollutant Toxicity 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940097957 dexamethasone 2 mg Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- GAKUNXBDVGLOFS-DUZKARGPSA-N (1-acetyloxy-3-hexadecanoyloxypropan-2-yl) (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COC(C)=O)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC GAKUNXBDVGLOFS-DUZKARGPSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001382 Adrenal suppression Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000001599 crocus sativus l. flower extract Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940076591 saffron extract Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
Description
본 발명은 피부질환, 특히 알레르기성 또는 염증성 피부질환 개선, 치료 또는 예방용 조성물에 관한 것으로, 보다 상세하게는 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 치료 또는 예방용 약학 조성물, 알레르기성 또는 염증성 피부질환 치료 또는 예방용 동물용 약학 조성물, 알레르기성 또는 염증성 피부질환 개선용 식품 조성물, 또는 알레르기성 또는 염증성 피부질환 개선용 사료 조성물에 관한 것이다. The present invention relates to a composition for improving, treating or preventing skin diseases, particularly allergic or inflammatory skin diseases, and more particularly, a pharmaceutical composition for the treatment or prevention of allergic or inflammatory skin diseases comprising the juice of Jasper Cheonin Guk as an active ingredient , It relates to a pharmaceutical composition for animals for the treatment or prevention of allergic or inflammatory skin diseases, a food composition for improving allergic or inflammatory skin diseases, or a feed composition for improving allergic or inflammatory skin diseases.
사람의 피부는 진피와 표피로 구성되어 있다. 특히, 피부의 최외각에 위치하고 있는 표피는 외부로부터의 다양한 자극, 예를 들면 화학 물질, 대기 오염 물질, 건조한 환경, 자외선 등의 물리화학적 자극인자에 대한 방어와 피부를 통한 체내 수분의 과도한 발산을 막는 보호 기능을 수행하고 있다. Human skin consists of the dermis and epidermis. In particular, the epidermis, located at the outermost part of the skin, protects against various stimuli from the outside, such as physicochemical stimuli such as chemicals, air pollutants, dry environments, and ultraviolet rays, and prevents excessive release of body moisture through the skin. It performs a protective function of preventing.
표피 중에서도 가장 바깥에 존재하는 각질층은 각질 형성세포로부터 형성되며, 분화가 완결된 각질세포와 그를 둘러싼 지질층으로 구성되어 있다. 각질세포는 일정 기간이 경과하면 피부에서 탈락되고, 표피 최하층으로부터 올라온 새로운 각질형성세포가 그 기능을 대신하게 되는데, 이러한 반복적인 일련의 변화 과정을 표피 분화(epidermis differentiation) 또는 각화(keratinization)라 한다. 이러한 각화 과정에서 각질형성세포는 천연보습인자(Natural Moisturizing Factor; NMF)와 세포 간 지질을 생성하면서 각질층을 형성하여, 각질층이 견고함과 유연성을 갖도록 하여 외부와의 차단층 역할을 하는 피부장벽으로서의 기능을 보유하게 된다.Among the epidermis, the outermost stratum corneum is formed from keratinocytes, and consists of keratinocytes that have been differentiated and the lipid layer surrounding them. Keratinocytes are eliminated from the skin after a certain period of time, and new keratinocytes raised from the lowermost layer of the epidermis take over their function.These repetitive processes of change are called epidermis differentiation or keratinization. . In the process of keratinization, keratinocytes form a stratum corneum while generating natural moisturizing factor (NMF) and intercellular lipids, making the stratum corneum firm and flexible, acting as a barrier to the outside as a skin barrier. You will have the function.
이러한 각질층은 과도한 세안이나, 목욕 등의 생활 습관적 요소나, 건조한 대기 오염 물질 등의 환경적인 요인, 및 아토피성 피부나 노인성 피부 같은 내인성 질환 등으로 인해 쉽게 그 기능이 손실될 수 있다. 실제로 현대에 들어서 피부에 대한 위해 요인이 점점 증가되고 있으며, 식생활 양상의 변화로 각질층의 생성 및 탈락 속도가 늦어지고, 각질형성세포의 기능 저하로 각질층의 보습인자와 지질의 양이 감소됨에 따라, 각질층이 정상적인 피부 장벽 기능을 발휘하지 못하는 피부를 가진 사람들이 증가하고 있는 추세이다.The stratum corneum may easily lose its function due to excessive washing, lifestyle factors such as bathing, environmental factors such as dry air pollutants, and endogenous diseases such as atopic skin or senile skin. In fact, in modern times, as harmful factors to the skin are gradually increasing, the rate of formation and dropout of the stratum corneum is slowed due to changes in dietary habits, and the amount of moisturizing factors and lipids in the stratum corneum decreases due to the decline in the function of keratinocytes. There is an increasing trend of people with skin whose stratum corneum does not function as a normal skin barrier.
특히 아토피 피부염은 최근 들어, 유병률이 급격히 증가함에 따라 그 위험성이 크게 부각되고 있는 알레르기성 또는 염증성 피부질환으로 유전적인 요인과 면역계 결핍에 관련 있는 것으로 추정될 뿐 아직 정확한 원인은 밝혀진 바 없고, 환경 및 식생활 개선을 통해 다소 완화되는 것으로 기대될 뿐 근본적인 치료방법이 전무한 실정이다.In particular, atopic dermatitis is an allergic or inflammatory skin disease that has a high risk as the prevalence of atopic dermatitis increases rapidly in recent years.It is estimated that it is related to genetic factors and immune system deficiency, but the exact cause has not yet been identified. It is expected to be somewhat alleviated through improvement of diet, but there is no fundamental treatment method.
현재까지 밝혀진 바에 따르면 아토피 피부염은 인체에 접촉하거나 들어온 알레르기 유발물질을 제거하는 과정에서 비만세포에 IgE가 생기게 되고, 추후 동일한 알레르기 유발물질과 접촉하거나 들어오게 되면 인체가 알레르기 유발물질에 대해 과민반응을 일으켜서, 히스타민을 발생하게 됨으로써 아토피 피부염이 발병하게 된다. It has been found that atopic dermatitis causes IgE to be produced in mast cells in the process of removing allergens that have come into contact with or in the body, and if it comes into contact with or comes in with the same allergens, the human body becomes hypersensitive to allergens. As a result, histamine is produced, leading to atopic dermatitis.
아토피 피부염의 치료제로는 주로 스테로이드 외용제, 항히스타민제, 칼시뉴린 저해제, 항생제, 자외선 요법 등이 사용되어 왔으나, 스테로이드의 경우 피부층을 지나 혈관까지 흡수됨에 따라 장기 사용할 경우, 피부위축, 모세혈관 확장 등 이상반응이 발생하였으며, 부신 억제 유발 위험이 있는 등 각종 부작용 때문에 제한이 있으므로, 상대적으로 부작용이 적으며 아토피 피부염을 치료할 수 있는 새로운 치료제에 대한 관심이 증대되고 있다.As the treatment for atopic dermatitis, steroid topical drugs, antihistamines, calcineurin inhibitors, antibiotics, and ultraviolet therapy have been mainly used.However, in the case of long-term use, skin atrophy, capillary dilation, etc. A reaction has occurred and there is a limitation due to various side effects such as a risk of inducing adrenal suppression, so there are relatively few side effects and interest in new treatments capable of treating atopic dermatitis is increasing.
한편 자주천인국(Echinacea purpurea)은 국화과의 여러해살이 식물로서 북미가 원산이며, 꽃이 화려해서 전 세계적으로 관상용으로 널리 재배되고 있으며, 면역력을 증강시켜 감기나 각종 바이러스 감염의 치료제로도 사용되고 있다.On the other hand, Echinacea purpurea is a perennial plant of the Asteraceae family, native to North America, and is widely cultivated for ornamental purposes all over the world because of its gorgeous flowers, and is also used as a remedy for colds and various viral infections by enhancing immunity.
본 발명이 해결하고자 하는 과제는 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 치료 또는 예방용 약학 조성물을 제공하는 것이다.The problem to be solved by the present invention is to provide a pharmaceutical composition for the treatment or prevention of allergic or inflammatory skin diseases, comprising the juice of Jasper Cheonin Guk as an active ingredient.
본 발명이 해결하고자 하는 다른 과제는 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 치료 또는 예방용 동물용 약학 조성물을 제공하는 것이다.Another problem to be solved by the present invention is to provide a pharmaceutical composition for animals for the treatment or prevention of allergic or inflammatory skin diseases, comprising the juice of Jagalcheonin Guk as an active ingredient.
본 발명이 해결하고자 하는 또 다른 과제는 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 개선용 식품 조성물을 제공하는 것이다.Another problem to be solved by the present invention is to provide a food composition for improving allergic or inflammatory skin diseases, including the juice of Jajucheonin-guk as an active ingredient.
본 발명이 해결하고자 하는 또 다른 과제는 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 개선용 사료 조성물을 제공하는 것이다.Another problem to be solved by the present invention is to provide a feed composition for improving allergic or inflammatory skin diseases, including the juice of Jagalcheoninguk as an active ingredient.
본 발명은 상기 과제를 달성하기 위하여, 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 치료 또는 예방용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for the treatment or prevention of allergic or inflammatory skin diseases, comprising the juice of Jagalcheonin Guk as an active ingredient in order to achieve the above object.
본 발명의 일 실시예에 의하면, 상기 알레르기성 또는 염증성 피부질환은 피부 염증, 습진, 접촉성 피부염, 아토피 피부염, 지루성 피부염, 만성단순태선, 간찰진, 박탈 피부염, 구진상 두드러기, 건선, 건선관절염, 일광 피부염, 일광화상 및 여드름 중에서 선택되는 어느 하나의 피부질환일 수 있다.According to an embodiment of the present invention, the allergic or inflammatory skin disease is skin inflammation, eczema, contact dermatitis, atopic dermatitis, seborrheic dermatitis, chronic lichen planus, intermittent dermatitis, deprived dermatitis, papular urticaria, psoriasis, psoriatic arthritis. , Sun dermatitis, sunburn and acne may be any one of the skin diseases selected from.
본 발명의 일 실시예에 의하면, 상기 자주천인국은 자주천인국의 줄기, 잎 또는 지상부 전초일 수 있다.According to an embodiment of the present invention, the self-made heaven-in-guk may be a stem, leaf, or above-ground outpost of the self-made heaven-in-guk.
본 발명의 일 실시예에 의하면, 상기 약학 조성물은 경구용 제제일 수 있다.According to an embodiment of the present invention, the pharmaceutical composition may be an oral formulation.
본 발명의 일 실시예에 의하면, 상기 경구용 제제는 산제, 과립제, 정제, 캡슐제, 트로키제, 현탁액, 에멀젼, 시럽 또는 에어로졸일 수 있다.According to an embodiment of the present invention, the oral preparation may be a powder, granule, tablet, capsule, troche, suspension, emulsion, syrup or aerosol.
또한 본 발명은 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 치료 또는 예방용 동물용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for animals for the treatment or prevention of allergic or inflammatory skin diseases, comprising the juice of Jasper Cheon In Guk as an active ingredient.
또한 본 발명은 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 개선용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for improving allergic or inflammatory skin diseases, including the juice of Jajucheonin-guk as an active ingredient.
본 발명의 일 실시예에 의하면, 상기 식품 조성물은 산제, 과립제, 정제, 캡슐제, 환제, 엑스제, 젤리 제형, 티백 제형 또는 음료 제형일 수 있다.According to an embodiment of the present invention, the food composition may be a powder, granule, tablet, capsule, pill, extract, jelly formulation, tea bag formulation, or beverage formulation.
본 발명의 일 실시예에 의하면, 상기 식품 조성물은 알레르기성 또는 염증성 피부질환 개선용 건강기능식품일 수 있다.According to an embodiment of the present invention, the food composition may be a health functional food for improving allergic or inflammatory skin diseases.
또한 본 발명은 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 개선용 사료 조성물을 제공한다.In addition, the present invention provides a feed composition for improving allergic or inflammatory skin diseases, comprising the juice of Jagalcheoninguk as an active ingredient.
또한 본 발명은 인간, 또는 인간을 제외한 동물에게 상기 조성물을 경구 투여하는 알레르기성 또는 염증성 피부질환의 치료방법을 제공한다.In addition, the present invention provides a method for treating allergic or inflammatory skin diseases in which the composition is orally administered to humans or animals other than humans.
또한 본 발명은 알레르기성 또는 염증성 피부질환 치료용 의약, 또는 동물용 의약 제조를 위한 자주천인국 착즙액의 신규 용도를 제공한다.In addition, the present invention provides a novel use of the juice for the treatment of allergic or inflammatory skin diseases, or for the manufacture of veterinary medicine.
본 발명의 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 개선, 치료 또는 예방용 조성물은 염증성 피부질환 동물 모델의 귀의 부종을 감소시키고, 혈액 검사에서 전체 백혈구, 호중구, 호산구, 혈중 IgE 등의 수준을 감소시키므로 알레르기성 또는 염증성 피부질환 치료 또는 예방용 약학 조성물, 알레르기성 또는 염증성 피부질환 치료 또는 예방용 동물용 약학 조성물, 알레르기성 또는 염증성 피부질환 개선용 식품 조성물, 또는 알레르기성 또는 염증성 피부질환 개선용 사료 조성물로 활용될 수 있다.The composition for improving, treating, or preventing allergic or inflammatory skin diseases comprising the juice of Jasper Cheonin Guk as an active ingredient of the present invention reduces swelling of the ear in an animal model of inflammatory skin disease, and in blood tests, total leukocytes, neutrophils, eosinophils, As it reduces the level of IgE, pharmaceutical compositions for treating or preventing allergic or inflammatory skin diseases, pharmaceutical compositions for animals for treating or preventing allergic or inflammatory skin diseases, food compositions for improving allergic or inflammatory skin diseases, or allergic or It can be used as a feed composition for improving inflammatory skin diseases.
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 발명자들은 알레르기성 또는 염증성 피부질환 동물 모델에서 자주천인국 착즙액을 경구 투여하여, 귀의 부종, 혈액 검사에서 전체 백혈구, 호중구, 호산구, 혈중 IgE 등의 수준을 평가하였다. 그 결과, 자주천인국 착즙액의 경구 투여에 의해 알레르기성 또는 염증성 피부질환에 현저한 치료 효능이 있음을 확인하였다.The inventors of the present invention evaluated the level of total leukocytes, neutrophils, eosinophils, blood IgE, etc. in ear edema and blood tests by orally administering Jagal Cheonin Guk juice in an allergic or inflammatory skin disease animal model. As a result, it was confirmed that the oral administration of Jajucheonin-guk juice has a remarkable therapeutic effect on allergic or inflammatory skin diseases.
본 발명은 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 치료 또는 예방용 약학 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for the treatment or prevention of allergic or inflammatory skin diseases, comprising a juice juice of Jagalcheoninguk as an active ingredient.
또한 본 발명은 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 치료 또는 예방용 동물용 약학 조성물에 관한 것이다.In addition, the present invention relates to a pharmaceutical composition for animals for the treatment or prevention of allergic or inflammatory skin diseases, comprising the juice of Jagalcheoninguk as an active ingredient.
본 발명에서 사용되는 용어 '착즙액'은 자주천인국 줄기, 잎 또는 지상부 전초를 압착, 또는 분쇄 및 압착하여 얻은 착즙액, 이들로부터 분획한 분획물, 이들 착즙액 또는 분획물을 추가적으로 농축한 농축물, 이를 정제 또는 분리한 정제물도 포함하고, 상기 착즙액, 분획물, 농축물 또는 정제물을 건조한 건조물 또는 그를 분쇄한 분말을 포함하는 의미로 사용된다. The term'juice liquor' as used in the present invention refers to a juice obtained by compressing, pulverizing and compressing the stem, leaves, or above-ground outposts, fractions fractionated from them, concentrates obtained by additionally concentrating these juices or fractions, Purified or separated purified product is also included, and the juice, fraction, concentrate, or purified product is dried or dried or pulverized.
상기 자주천인국 착즙액 분말 1 중량부를 제조하기 위해 건조되지 않은 자주천인국 약 20 내지 100 중량부, 바람직하게는 30 내지 60 중량부가 필요하고, 상기 자주천인국 착즙액 분말 1 중량부를 제조하기 위해 자주천인국 착즙액 10 내지 50 중량부, 바람직하게는 15 내지 30 중량부가 필요하다. In order to prepare 1 part by weight of the Jasper Cheonin Guk juice powder, about 20 to 100 parts by weight, preferably 30 to 60 parts by weight of undried Jasper Cheoninguk juice, and 1 part by weight of the Jasper Cheon In Guk juice powder 10 to 50 parts by weight of the liquid, preferably 15 to 30 parts by weight, are required.
상기 정제물의 제조를 위해 분자량 컷-오프 값을 갖는 한외 여과막을 통과시키거나, 또는 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 부가할 수 있다.For the preparation of the purified product, various additionally carried out, such as passing through an ultrafiltration membrane having a molecular weight cut-off value, or separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity) Purification methods can be added.
상기 자주천인국 착즙액은 물, 탄소수 1 내지 4의 알코올 또는 그들의 혼합 용매에 의한 자주천인국 수성 추출물이나, 또는 이들을 헥산, 에틸아세테이트 등으로 분획한 지용성 추출물에 비해 알레르기성 또는 염증성 피부질환 치료 효능이 현저히 뛰어나다.The Jagal Cheonin Guk juice is remarkably effective in treating allergic or inflammatory skin diseases compared to the aqueous extract of Jagal Cheonin Guk using water, alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, or a fat-soluble extract fractionated with hexane, ethyl acetate, etc. outstanding.
상기 자주천인국 착즙액은 자주천인국(Echinacea purpurea)의 잎, 줄기 또는 이를 포함하는 지상부 전초의 착즙액일 수 있으나, 경구 투여에 의한 알레르기성 또는 염증성 피부질환 감소 효능은 지상부 전초의 착즙액이 뛰어나다.The juice of the Jasper Cheonin Guk may be a juice of leaves, stems of Echinacea purpurea , or the above-ground outposts including the same, but the efficacy of reducing allergic or inflammatory skin diseases by oral administration is excellent.
본 발명에서 사용되는 용어 '알레르기성 또는 염증성 피부질환'은 피부에서 일어나는 알레르기성 또는 염증성 반응을 수분하는 피부질환을 제한없이 포함할 수 있으며, 예를 들어 피부 염증, 습진, 접촉성 피부염, 아토피 피부염, 지루성 피부염, 만성단순태선, 간찰진, 박탈 피부염, 구진상 두드러기, 건선, 건선관절염, 일광 피부염, 일광화상 및 여드름 중에서 선택되는 어느 하나의 피부질환일 수 있으며, 바람직하게는 만성 난치성 알레르기성 또는 염증성 피부질환인 아토피 피부염일 수 있다.The term'allergic or inflammatory skin disease' used in the present invention may include, without limitation, skin diseases that moisturize an allergic or inflammatory reaction occurring in the skin, for example, skin inflammation, eczema, contact dermatitis, atopic dermatitis. , Seborrheic dermatitis, chronic lichen planus, interstitial, deprived dermatitis, papular urticaria, psoriasis, psoriatic arthritis, sun dermatitis, sunburn and acne, preferably any one skin disease, preferably chronic refractory allergic or It may be atopic dermatitis, an inflammatory skin disease.
상기 '약학 조성물', '의약', '동물용 약학 조성물' 또는 '동물용 의약'은 유효성분으로 자주천인국 착즙액 이외에, 약학 조성물 등의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The'pharmaceutical composition','pharmaceutical','veterinary pharmaceutical composition', or'veterinary medicine' is an active ingredient, in addition to the juice of Jasper Cheonin Guk, a suitable carrier, excipient, and diluent commonly used in the manufacture of pharmaceutical compositions, etc. Can include.
상기 '담체'는 세포 또는 조직 내로의 화합물의 부가를 용이하게 하는 화합물이다. 상기 '부형제'는 유효성분에 적당한 형태를 부여하여 제형화하거나 양을 증가시켜 사용하기 편리하게 하기 위해 첨가하는 화합물이다. 상기 '희석제'는 대상 화합물의 생물학적 활성 형태를 안정화시킬 뿐만 아니라, 화합물을 용해시키게 되는 물에서 희석되는 화합물이다. The'carrier' is a compound that facilitates the addition of the compound into cells or tissues. The'excipient' is a compound added to provide an appropriate form to the active ingredient to be formulated or to increase the amount for convenient use. The'diluent' is a compound that is diluted in water to dissolve the compound as well as stabilize the biologically active form of the target compound.
상기 담체, 부형제 및 희석제로는 특별히 한정할 필요는 없으나 예를 들어, 유당, 포도당, 설탕, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 들 수 있다.The carrier, excipient, and diluent are not particularly limited, but for example, lactose, glucose, sugar, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
상기 약학 조성물, 의약, 동물용 약학 조성물 또는 동물용 의약의 사용량은 환자 또는 치료대상 동물의 나이, 성별, 체중에 따라 달라질 수 있으며, 무엇보다도, 치료대상 개체의 상태, 치료 대상 질환의 특정한 카테고리 또는 종류, 투여 경로, 사용되는 치료제의 속성에 의존적일 것이다.The amount of use of the pharmaceutical composition, medicament, veterinary pharmaceutical composition or veterinary medicament may vary depending on the age, sex, and weight of the patient or the animal to be treated, and above all, the condition of the subject to be treated, a specific category of the disease to be treated, or It will depend on the type, route of administration and the nature of the therapeutic agent used.
상기 약학 조성물, 의약, 동물용 약학 조성물 또는 동물용 의약은 체내에서 활성성분의 흡수도, 배설속도, 환자 또는 치료대상 동물의 연령 및 체중, 성별 및 상태, 치료할 질병의 중증정도 등에 따라 적절히 선택되나, 일반적으로 1일 10 내지 5,000 mg, 바람직하게는 50 내지 4,000 mg, 더욱 바람직하게는 100 내지 3,000 mg, 가장 바람직하게는 200 내지 2,000 mg으로 투여하는 것이 바람직하다. 이렇게 제형화된 단위 투여형 제제는 필요에 따라 일정시간 간격으로 수회 투여할 수 있다.The pharmaceutical composition, medicament, veterinary pharmaceutical composition or veterinary medicament is appropriately selected according to the absorption of the active ingredient in the body, the excretion rate, the age and weight, sex and condition of the patient or the animal to be treated, and the severity of the disease to be treated. , In general, it is preferred to administer 10 to 5,000 mg per day, preferably 50 to 4,000 mg, more preferably 100 to 3,000 mg, and most preferably 200 to 2,000 mg per day. The unit dosage form formulation thus formulated may be administered several times at regular time intervals as needed.
상기 약학 조성물, 의약, 동물용 약학 조성물 또는 동물용 의약은 개별적으로 예방제 또는 치료제로서 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다.The pharmaceutical composition, medicament, veterinary pharmaceutical composition, or veterinary medicament may be individually administered as a prophylactic or therapeutic agent, or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with a conventional therapeutic agent.
상기 약학 조성물, 의약, 동물용 약학 조성물 또는 동물용 의약은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 트로키제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구용 제제로 제형화하여 사용될 수 있다. 제형화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.The pharmaceutical composition, medicament, veterinary pharmaceutical composition, or veterinary medicament is formulated and used in oral preparations such as powders, granules, tablets, capsules, troches, suspensions, emulsions, syrups, aerosols, etc., according to a conventional method. I can. In the case of formulation, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제, 트로키제 등이 포함되며, 이러한 고형 제제는 상기 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트, 설탕 또는 유당, 젤라틴 등을 섞어 조제될 수 있다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, troches, and the like, and such solid preparations include at least one excipient for the compound, such as starch, calcium carbonate, sugar or lactose, gelatin. It can be prepared by mixing and the like. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc may be used. Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included. .
상기 알레르기성 또는 염증성 피부질환의 치료방법은 인간, 또는 인간을 제외한 동물, 특히 포유동물에게 상기 조성물을 경구 투여하는 것으로, 예를 들어 알레르기성 또는 염증성 피부질환을 가진 치료대상 개체에게 상기 조성물을 경구 투여하는 것이다.The treatment method of the allergic or inflammatory skin disease is to orally administer the composition to humans or non-human animals, especially mammals, for example, oral administration of the composition to an individual to be treated with an allergic or inflammatory skin disease. It is to administer.
상기 치료를 위한 투여량, 투여 방법 및 투여 횟수는 상기 약학 조성물, 의약, 동물용 약학 조성물 또는 동물용 의약의 투여량, 투여 방법 및 투여 횟수를 참고할 수 있다.The dosage, administration method, and number of administrations for the treatment may refer to the dosage, administration method, and number of administrations of the pharmaceutical composition, medicine, veterinary pharmaceutical composition or animal medicine.
본 발명은 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 개선용 식품 조성물에 관한 것이다.The present invention relates to a food composition for improving allergic or inflammatory skin diseases, comprising the juice of Jajucheoninguk as an active ingredient.
상기 '식품 조성물'은 유효성분으로 자주천인국 착즙액 이외에, 식품 제조에 통상적으로 사용되는 식품의 기준 및 규격('식품공전')에 기재된 식품으로 사용가능한 식품 원료, 식품첨가물 공전에 기재된 식품첨가물을 포함할 수 있다.The'food composition' includes food ingredients and food additives described in the Code of Food Additives, which can be used as foods described in the standards and standards of foods commonly used in food manufacturing ('Food Code'), in addition to the juice juice of Jasper Cheonin Guk as an active ingredient. Can include.
상기 식품조성물은 특별히 한정할 필요는 없으나 예를 들어 탄수화물 및 향미제를 포함할 수 있다. 상기 탄수화물은 단당류, 예를 들어, 포도당, 과당 등; 이당류, 예를 들어 말토스, 설탕, 유당 등; 올리고당 또는 폴리사카라이드, 예를 들어 덱스트린, 물엿, 사이클로덱스트린 등; 당알코올, 예를 들어 자일리톨, 소르비톨, 에리트리톨 등을 사용할 수 있다. 상기 향미제는 천연 향미제[타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등)] 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.The food composition is not particularly limited, but may include, for example, carbohydrates and flavoring agents. The carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sugar, lactose, and the like; Oligosaccharides or polysaccharides such as dextrin, starch syrup, cyclodextrin, and the like; Sugar alcohols such as xylitol, sorbitol, erythritol, and the like can be used. The flavoring agent may be a natural flavoring agent [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)] and a synthetic flavoring agent (saccharin, aspartame, etc.).
상기 자주천인국 착즙액을 유효성분으로 식품 조성물을 제조하는 경우 자주천인국 착즙액은 알레르기성 또는 염증성 피부질환 개선 효능을 나타내는 함량이면 특별히 한정할 필요는 없으나, 예를 들어 0.1 내지 99 중량%, 0.5 내지 95 중량%, 1 내지 90 중량%, 2 내지 80 중량%, 3 내지 70 중량%, 4 내지 60 중량%, 5 내지 50 중량%로 포함될 수 있다.In the case of preparing a food composition using the juice of Jagalcheoninguk as an active ingredient, the juice of Jagaloninguk does not need to be particularly limited as long as it has an effect of improving allergic or inflammatory skin diseases, but, for example, 0.1 to 99% by weight, 0.5 to It may be included in 95% by weight, 1 to 90% by weight, 2 to 80% by weight, 3 to 70% by weight, 4 to 60% by weight, 5 to 50% by weight.
상기 식품 조성물에서 유효성분인 자주천인국 착즙액은 섭취자의 상태, 체중, 질병의 유무나 정도 및 기간에 따라 다르지만, 통상의 기술자에 의해 적절하게 선택될 수 있다. 예를 들어 1일 투여량을 기준으로 1일 10 내지 5,000 mg, 바람직하게는 50 내지 4,000 mg, 더욱 바람직하게는 100 내지 3,000 mg, 가장 바람직하게는 200 내지 2,000 mg일 수 있고, 투여 횟수는 특별히 한정할 필요는 없으나 1일 3회 내지 1주일에 1회의 범위 내에서 통상의 기술자가 조절할 수 있다. 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 범위 이하일 수 있다.In the food composition, the juice juice of Jajucheonin-guk, which is an active ingredient, varies depending on the condition, weight, and the presence or absence of disease and the duration of the ingestion, but may be appropriately selected by a skilled person. For example, it may be 10 to 5,000 mg, preferably 50 to 4,000 mg, more preferably 100 to 3,000 mg, most preferably 200 to 2,000 mg per day, based on the daily dosage, and the number of administration is particularly Although it does not need to be limited, it can be adjusted by a person skilled in the art within the range of 3 times a day to once a week. In the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, it may be less than the above range.
상기 식품 조성물은 특별히 한정할 필요는 없으나 예를 들어 산제, 과립제, 정제, 캡슐제, 환제, 엑스제, 젤리 제형, 티백 제형 또는 음료 제형일 수 있다.The food composition is not particularly limited, but may be, for example, a powder, a granule, a tablet, a capsule, a pill, an extract, a jelly formulation, a tea bag formulation, or a beverage formulation.
또한 일반 식품에 알레르기성 또는 염증성 피부질환 개선 기능성을 부여하기 위하여 상기 자주천인국 착즙액을 첨가할 수 있다. 첨가가 가능한 식품은, 특별히 한정할 필요는 없으나 예를 들어 식품위생법 제7조에 따른 식품의 기준 및 규격('식품공전')에 예시된 과자류, 빵 또는 떡류, 코코아가공품류 또는 초콜릿류, 식육 또는 알가공품, 어육가공품, 두부류 또는 묵류, 면류, 다류, 커피, 음료류, 특수용도식품, 장류, 조미식품, 드레싱류, 김치류, 젓갈류, 절임식품, 조림식품, 주류, 건포류, 기타 식품류 등에 첨가될 수 있다. 또한 축산물위생관리법 제4조에 따른 축산물의 가공기준 및 성분규격('축산물공전')에 예시된 유가공품, 식육가공품 및 포장육, 알가공품에 첨가될 수 있다.In addition, in order to impart the function of improving allergic or inflammatory skin diseases to general foods, the juice of Jagalcheoninguk may be added. Foods that can be added do not need to be particularly limited, but for example, confectionery, bread or rice cakes, processed cocoa products or chocolates, meat, etc. as exemplified in the food standards and standards ('Food Code') according to Article 7 of the Food Sanitation Act. Egg processed products, processed fish products, tofu or jelly, noodles, tea, coffee, beverages, special purpose foods, pastes, seasoned foods, dressings, kimchi, salted fish, pickles, stewed foods, alcoholic beverages, raisins, and other foods. Can be. In addition, it may be added to dairy products, processed meat products and packaged meats, and egg products exemplified in the processing standards and ingredient specifications of livestock products according to Article 4 of the Livestock Hygiene Management Act ('Livestock Products Code').
한편 상기 자주천인국 착즙액을 유효성분으로 하는 식품 조성물은 알레르기성 또는 염증성 피부질환 개선용 건강기능식품, 예를 들어 아토피 피부염 개선용 건강기능식품, "과민면역반응 완화에 도움을 주는 건강기능식품" 또는 "면역과민반응에 의한 피부상태 개선에 도움을 주는 건강기능식품"으로 이용될 수 있다. On the other hand, the food composition containing the juice of Jaju Cheonin Guk as an active ingredient is a health functional food for improving allergic or inflammatory skin diseases, for example, a health functional food for improving atopic dermatitis, "health functional food that helps alleviate hyperimmune reactions" Or, it may be used as "health functional food that helps improve skin condition due to immune hypersensitivity reaction".
상기 '건강기능식품'은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 법적 기준에 따라 제조(가공을 포함)한 식품(건강기능식품에 관한 법률 제3조 제1호)을 말한다. 상기 '건강기능식품'은 국가마다 용어나 범위에 차이가 있을 수 있으나, 미국의 '식이 보충제(Dietary Supplement)', 유럽의 '식품 보충제(Food Supplemnet)', 일본의 '보건기능식품' 또는 '특정보건용식품(Food for Special Health Use, FoSHU)', 중국의 '보건식품' 등에 해당할 수 있다.The'health functional food' refers to a food manufactured (including processing) in accordance with legal standards using raw materials or ingredients having useful functions for the human body (Article 3, No. 1 of the Health Functional Food Act). The'health functional food' may differ in terms or ranges from country to country, but'Dietary Supplement' in the United States,'Food Supplemnet' in Europe,'Health Functional Food' in Japan or ' It may correspond to'Food for Special Health Use (FoSHU)' and'Health Food' in China.
상기 식품 조성물 또는 건강기능식품은 식품첨가물을 추가로 포함할 수 있으며, 식품첨가물로서의 적합여부는 다른 규정이 없는 한 '식품첨가물공전'의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 따른다.The food composition or health functional food may additionally contain food additives, and the suitability as a food additive shall be determined according to the standards and standards for the relevant item in accordance with the general rules and general test methods of the'Food Additive Code' unless otherwise specified. Follows.
또한 상기 건강기능식품에는 자주천인국 착즙액과 함께 "과잉면역반응 완화에 도움을 주는 건강기능식품" 또는 "면역과민반응에 의한 피부상태 개선에 도움을 주는 건강기능식품"에 사용되는 '기능성 원료'로 고시된 원료 또는 개별인정된 원료로서, Enterococcus feacalis 가열처리건조분말, 구아바잎추출물 등 복합물, 다래추출물, 소엽추출물, 피카오프레토 분말 등 복합물, 합성 PLAG, L. sakei Probio 65, 감마리놀렌산 함유 유지, 과채유래유산균(L. plantarum CJLP133), 프로바이오틱스ATP 등의 과잉면역반응 완화와 관련된 건강기능식품 소재를 복합하여 사용할 수 있다.In addition, the above health functional foods are'functional raw materials' used in "health functional foods that help alleviate hyperimmune reactions" or "health functional foods that help improve skin conditions due to immune hypersensitivity reactions" together with Jagal Cheonin Guk juice. As a raw material notified as or individually approved, Enterococcus feacalis heat-treated dry powder, guava leaf extract and other complexes, saffron extract, lobular extract, picaopreto powder, and other complexes, synthetic PLAG, L. sakei Probio 65, oil containing gammarinolenic acid , Fruit and vegetable-derived lactic acid bacteria ( L. plantarum CJLP133), probiotics ATP, and other health functional food materials related to relieving hyperimmune reactions can be used in combination.
본 발명은 자주천인국 착즙액을 유효성분으로 포함하는 알레르기성 또는 염증성 피부질환 개선용 사료 조성물에 관한 것이다.The present invention relates to a feed composition for improving allergic or inflammatory skin diseases, comprising the juice of Jagalcheoninguk as an active ingredient.
상기 '사료 조성물'은 유효성분으로 자주천인국 착즙액 이외에, 식품의 기준 및 규격('식품공전')에 기재된 식품으로 사용가능한 식품 원료, 식품첨가물 공전에 기재된 식품첨가물을 사용할 수 있고, 식품으로 사용가능한 식품 원료 또는 식품첨가물이 아니더라도 '사료 등의 기준 및 규격' 별표 1의 단미사료의 범위에 해당하는 원료, 별표 2의 보조사료의 범위에 해당하는 원료를 사용할 수 있다.The'feed composition' can be used as an active ingredient, as well as food ingredients and food additives listed in the Food Additives Code, which can be used as foods specified in the standards and standards of food ('Food Code'), in addition to the juice of Jasper Cheonin Guk. Even if it is not a possible food raw material or food additive, raw materials that fall within the range of sweet feeds in Appendix 1 of'Standards and Specifications for Feed, etc.' and raw materials that fall within the range of auxiliary feeds in Appendix 2 can be used.
상기 '사료 조성물'은 '사료 등의 기준 및 규격'에 따른 보조사료 중 추출제일 수 있고, 상기 보조사료를 포함하는 배합사료일 수 있다.The'feed composition' may be an extractant among auxiliary feeds according to'standards and standards for feed, etc.', and may be a blended feed including the auxiliary feed.
상기 자주천인국 착즙액을 유효성분으로 사료 조성물을 제조하는 경우 자주천인국 착즙액은 알레르기성 또는 염증성 피부질환 개선 효능을 나타내는 함량이면 특별히 한정할 필요는 없으나, 예를 들어 0.1 내지 99 중량%, 0.5 내지 95 중량%, 1 내지 90 중량%, 2 내지 80 중량%, 3 내지 70 중량%, 4 내지 60 중량%, 5 내지 50 중량%로 포함될 수 있다.In the case of preparing a feed composition using the juice of Jagalcheoninguk as an active ingredient, the juice of Jagalcheoninguk does not need to be particularly limited as long as it has an effect of improving allergic or inflammatory skin diseases, but, for example, 0.1 to 99% by weight, 0.5 to It may be included in 95% by weight, 1 to 90% by weight, 2 to 80% by weight, 3 to 70% by weight, 4 to 60% by weight, 5 to 50% by weight.
상기 사료 조성물에서 유효성분인 자주천인국 착즙액은 섭취 동물의 상태, 체중, 질병의 유무나 정도 및 기간에 따라 다르지만, 통상의 기술자에 의해 적절하게 선택될 수 있다. 예를 들어 1일 투여량을 기준으로 1 내지 5,000 mg, 바람직하게는 5 내지 2,000 mg, 더욱 바람직하게는 10 내지 1,000 mg, 더더욱 바람직하게는 20 내지 800 mg, 가장 바람직하게는 50 내지 500 mg일 수 있고, 투여 횟수는 특별히 한정할 필요는 없으나 1일 3회 내지 1주일에 1회의 범위 내에서 통상의 기술자가 조절할 수 있다. 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 범위 이하일 수 있다.In the feed composition, the juice of Jagalcheonin-guk, which is an active ingredient, varies depending on the condition, weight, and the presence or absence of disease and the duration of the ingested animal, but may be appropriately selected by a person skilled in the art. For example, 1 to 5,000 mg, preferably 5 to 2,000 mg, more preferably 10 to 1,000 mg, even more preferably 20 to 800 mg, most preferably 50 to 500 mg, based on daily dosage It may be, the number of administration is not particularly limited, but can be adjusted by a skilled person within the range of 3 times a day to once a week. In the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, it may be less than the above range.
이하, 바람직한 실시예를 들어 본 발명을 더욱 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이에 의하여 제한되지 않는다는 것은 당업계의 통상의 지식을 가진 자에게 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to preferred embodiments. However, these examples are for describing the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited thereto.
실험예 1Experimental Example 1
1. 실험동물 및 시료의 준비1. Preparation of experimental animals and samples
핀젤버르그사의 "모델번호: 0 347 318; Echinacea dried pressed juice(95 % native)"를 구매하여 자주천인국 착즙액(EPJ) 분말로 사용하였다. 상기 자주천인국 착즙액(EPJ) 분말은 전초를 착즙한 착즙액을 건조한 것이고, 자주천인국 착즙액 고형분 함량은 95 중량%이었다.Fingelberg's "Model No.: 0 347 318; Echinacea dried pressed juice (95% native)" was purchased and used as an EPJ powder. The Judge Cheonin Guk juice (EPJ) powder was dried from the juice obtained by extracting the outpost, and the JJJJJJ juice juice had a solid content of 95% by weight.
양성대조군 1로 "과잉면역반응 완화에 도움을 주는 건강기능식품"에 사용되는 '기능성 원료'로 고시된 '다래추출물'을 구입하여 사용하였다. 상기 다래추출물은 갈색의 분말로 추출물 고형분 함량은 41 중량%이었다.As a positive control group 1,'Styria extract', which is notified as a'functional raw material' used for "health functional food that helps alleviate hyperimmune reaction," was purchased and used. The edible extract was a brown powder, and the solid content of the extract was 41% by weight.
양성대조군 2로 '덱사메타손정(DEX)'을 구입하여 사용하였다. 상기 덱사메타손정은 흰색의 원형 정제로 정당 0.5 mg의 덱사메타손(dexamethasone)이 함유되어 있다. 'Dexamethasone Tablet (DEX)' was purchased and used as a positive control group 2. The dexamethasone tablet is a white round tablet containing 0.5 mg of dexamethasone per sugar.
실험동물은 재팬 에스엘씨(Japan SLC, Inc., Japan)에서 Nc/Nga 마우스(4주령, 숫컷)를 공급받아 사용하였다. NC/Nga 마우스는 IgE의 과생성에 의해 동반된 아토피성 피부염의 형태가 임상적으로나 조직학적으로 인간의 아토피 피부염의 병변과 매우 흡사한 양태를 나타내고, 종래 아토피 피부염 동물 모델로 활용된 사례가 많아 선택하였다. Experimental animals were supplied with Nc/Nga mice (4 weeks old, male) from Japan SLC, Inc., Japan and used. NC/Nga mice show a pattern of atopic dermatitis accompanied by overproduction of IgE, clinically and histologically, very similar to the lesions of human atopic dermatitis, and there are many cases that have been used as atopic dermatitis animal models. I chose.
고형사료와 물을 충분히 공급하고 온도 23±2 ℃, 상대습도 55±10 %, 환기횟수 10 내지 20 회/hr, 12 시간-12 시간(light-dark cycle) 및 조도 150 내지 300 Lux의 환경에서 사육하였다. Sufficient supply of solid feed and water, temperature 23±2 ℃, relative humidity 55±10%, ventilation frequency 10 to 20 times/hr, 12 hours to 12 hours (light-dark cycle) and illuminance 150 to 300 Lux. Breed.
사육 개시 전 NC/Nga 마우스의 귓바퀴 및 목뒤 부분을 면도기로 제모한 후, 제모제를 적량 도포하여 제모하였다. 시험물질 투여 전, 아토피 피부염을 유도하기 위해 1, 5, 8 및 12 일차에 총 4 회, 아토피 피부염 유발시약(Biostir AD, Biostir Inc., Japan)을 귓바퀴, 경배부 및 앞다리 위치의 등 부위에 균일하게 도포하였다. 14 일차에 피부 임상지수를 평가하고 순위화한 아토피 피부염 유발 수준에 따라 각 군의 평균수준이 최대한 균일하게 분포하도록 무작위법으로 분배하였다.Before the start of breeding, the auricle and the back of the neck of NC/Nga mice were depilated with a razor, and then, an appropriate amount of a depilatory agent was applied to remove the hair. Before administration of the test substance, atopic dermatitis-inducing reagent (Biostir AD, Biostir Inc., Japan) was applied to the back of the auricle, neck, and forelimbs 4 times in total on days 1, 5, 8 and 12 to induce atopic dermatitis. Evenly applied. On the 14th day, the skin clinical index was evaluated and distributed in a random method so that the average level of each group was distributed as uniformly as possible according to the ranked levels of atopic dermatitis.
시험물질 투여 개시 이후에도 아토피 피부염을 지속적으로 유발하기 위해 15, 19, 22, 26, 29, 33, 36, 40, 43 및 47 일차에 총 10 회, 아토피 피부염 유발시약을 귓바퀴, 경배부 및 앞다리 위치의 등 부위에 균일하게 도포하였다.In order to continuously induce atopic dermatitis even after the start of administration of the test substance, atopic dermatitis-inducing reagent was applied to the auricle, neck, and forelimb locations a total of 10 times on days 15, 19, 22, 26, 29, 33, 36, 40, 43 and 47. It was evenly applied to the back of the body.
모든 동물실험 과정은 NIH(National Institutes of Health)의 실험동물관리 규정(Principle of Laboratory Animal Care)을 준수하여 수행하였다.All animal testing procedures were performed in compliance with NIH (National Institutes of Health)'s Principle of Laboratory Animal Care.
아래 표 1과 같이 이들 중 1군은 아토피 피부염을 유발시키지 않은 정상대조군, 나머지 4군에 대해서는 2 주간 아토피 피부염을 유발시킨 후, 시험물질 투여를 개시하고 5 주간 계속 아토피 피부염을 유발하면서 제1-3군은 부형제를 제외한 착즙액 고형분을 기준으로 200 mg/kg, 그리고 제1-4군은 '다래추출물'의 추출물 고형분을 기준으로 200 mg/kg, 제1-5군은 '덱사메타손' 유효성분을 기준으로 2 mg/kg을 10 mL/kg 투여 액량을 기준으로 1일 1회 경구 투여하였다. 정상대조군 및 음성대조군은 비히클로 생리식염수를 10 mL/kg 경구 투여하였다.As shown in Table 1 below, group 1 of them induces atopic dermatitis for 2 weeks in the normal control group, and the remaining 4 groups induce atopic dermatitis for 2 weeks. Group 3 is 200 mg/kg based on the solid content of the juice extract excluding excipients, Groups 1-4 are 200 mg/kg based on the solid content of the extract of'Styria extract', and Groups 1-5 are the active ingredient of'Dexamethasone' 2 mg/kg was administered orally once a day based on a 10 mL/kg dose. The normal control group and the negative control group were orally administered 10 mL/kg of physiological saline as a vehicle.
2. 체중 측정 결과2. Weight measurement result
아토피 피부염 유발 개시 1, 14, 28, 42 및 49 일차 체중(g)을 측정하여 표 2에 나타내었다. Initiation of atopic dermatitis induction 1, 14, 28, 42 and 49 Days body weight (g) was measured and shown in Table 2.
제1-1군의 정상대조군과 제1-2군 내지 제1-5군 사이의 유의차는 * p<0.05, ** p<0.01, *** p<0.001; 제1-2군의 음성대조군과 제1-3군 내지 제1-5군 사이의 유의차는 # p<0.05, ## p<0.01Significant differences between the normal control group of group 1-1 and group 1-2 to group 1-5 were * p<0.05, ** p<0.01, *** p<0.001; Significant differences between the negative control group 1-2 and groups 1-3 to 1-5 were # p<0.05, ## p<0.01
아토피 피부염 유발 개시 14 일차에는 전체 시험군을 통틀어 통계적으로 유의한 체중 차이는 관찰되지 않았다.On the 14th day of the onset of atopic dermatitis induction, no statistically significant difference in body weight was observed across all test groups.
아토피 피부염 유발 개시 28 일차(시험물질 투여 14 일차)에 모든 시험물질 투여군인 제1-3군 내지 제1-5군의 체중은 정상대조군인 제1-1군에 비하여 유의하게 낮았고(p<0.05, p<0.05 및 p<0.001), 특히 덱사메타손을 투여한 제1-5군의 체중은 음성대조군인 제1-2군에 비해서도 유의하게 낮았다(p<0.01). On the 28th day of the onset of atopic dermatitis (day 14 of test substance administration), the body weights of all test substance-administered groups 1-3 to 1-5 were significantly lower than that of the normal control group 1-1 (p<0.05). , p<0.05 and p<0.001), in particular, the body weight of group 1-5 to which dexamethasone was administered was significantly lower than that of group 1-2, which is the negative control group (p<0.01).
아토피 피부염 유발 개시 42 일차(시험물질 투여 28 일차)에 덱사메타손을 투여한 제1-5군의 체중은 제1-1군의 정상대조군에 비하여 유의하게 낮았고(p<0.001), 제1-2군의 음성대조군에 비해서도 유의하게 낮았다(p<0.01). The body weight of groups 1-5 that were administered dexamethasone on the 42nd day of the onset of atopic dermatitis (day 28 of test substance administration) was significantly lower than that of the normal control group of group 1-1 (p<0.001) and group 1-2. Was significantly lower than that of the negative control group (p<0.01).
아토피 피부염 유발 개시 49 일차(시험물질 투여 35 일차)에 다래추출물을 투여한 제1-4군의 체중은 제1-1군의 정상대조군에 비하여 유의하게 낮았고(p<0.01), 덱사메타손을 투여한 제1-5군은 제1-1군은 물론 제1-2군에 비하여 유의하게 낮았다(p<0.001 및 p<0.01). On the 49th day (day 35 of test substance administration) on the onset of atopic dermatitis induction, the body weight of groups 1-4 that were administered sativa extract was significantly lower than that of the normal control group of group 1-1 (p<0.01), and dexamethasone was administered. Groups 1-5 were significantly lower than those of group 1-1 as well as group 1-2 (p<0.001 and p<0.01).
아토피 피부염 유발 개시 28 일차부터 49 일차까지 나타난 제1-5군의 유의적인 체중 감소는 면역억제제의 전신적 투여에 따른 부작용인 것으로 평가되었으며, 그 외 시험물질 투여군에서 관찰된 제1-1군 대비 체중의 감소는 대부분의 날짜에서 제1-2군 대비 유의한 차이가 관찰되지 않았기에, 시험물질의 투여에 의한 것은 아닌 것으로 평가된다.Significant weight loss in groups 1-5, which appeared from day 28 to day 49 of the onset of atopic dermatitis, was evaluated as a side effect of systemic administration of immunosuppressants. Since no significant difference was observed compared to group 1-2 in most of the dates, it was evaluated not due to the administration of the test substance.
3. 귀 부종 측정 결과3. Ear edema measurement result
아토피 피부염 유발 개시 1, 14, 28, 42 및 49 일차 귀 두께(mm)를 캘리퍼스로 측정하여 귀 부종 발생을 확인하여 표 3에 나타내었다.Initiation of atopic dermatitis induction 1, 14, 28, 42, and 49 Primary ear thicknesses (mm) were measured with a caliper to confirm the occurrence of ear edema, and are shown in Table 3.
제1-1군의 정상대조군과 제1-2군 내지 제1-5군 사이의 유의차는 * p<0.05, ** p<0.01, *** p<0.001; 제1-2군의 음성대조군과 제1-3군 내지 제1-5군 사이의 유의차는 # p<0.05, ## p<0.01Significant differences between the normal control group of group 1-1 and group 1-2 to group 1-5 were * p<0.05, ** p<0.01, *** p<0.001; Significant differences between the negative control group 1-2 and groups 1-3 to 1-5 were # p<0.05, ## p<0.01
아토피 피부염이 지속적으로 유발됨에 따라 아토피 피부염 유발 개시 28일차(시험물질 투여 14 일차)부터 시험 종료 시까지 제1-5군을 제외한 모든 아토피 유발군의 귀 두께 수준은 제1-1군에 비하여 유의하게 높았고(p<0.001, p<0.01 또는 p<0.05), 제1-5군의 귀 두께 수준은 제1-2군의 음성대조군에 비하여 유의하게 낮았다(p<0.001 또는 p<0.01). As atopic dermatitis is continuously induced, the ear thickness level of all atopic-inducing groups except for group 1-5 from day 28 of the initiation of atopic dermatitis to the end of the test from day 28 (day 14 of test substance administration) was significantly compared to that of group 1-1. Was significantly higher (p<0.001, p<0.01, or p<0.05), and the ear thickness level of group 1-5 was significantly lower than that of negative control group 1-2 (p<0.001 or p<0.01).
제1-3군의 자주천인국 착즙액 투여군은 제1-2군의 음성대조군에 비해 다소 귀 두께가 감소하는 경향을 보이고, 제1-4군의 다래추출물 투여군과 유사한 경향을 나타내었다.Compared to the negative control group of Group 1-2, the ear thickness of the group 1-3 administered with the extract of Jajucheonin-guk showed a tendency to decrease somewhat compared to the negative control group of Group 1-4, and showed a similar tendency to that of the group 1-4 administered with the extract.
4. 비장 중량 측정 결과4. Spleen weight measurement result
아토피 피부염 유발 개시 49 일차의 부검일에 비장을 적출하여 무게를 측정하고, 체중 및 체중에 대한 비율과 함께 표 4에 나타내었다. On the day of necropsy on the 49th day of the initiation of atopic dermatitis, the spleen was removed and the weight was measured, and the weight and the ratio to the body weight were shown in Table 4.
제1-1군의 정상대조군과 제1-2군 내지 제1-5군 사이의 유의차는 * p<0.05, ** p<0.01, *** p<0.001; 제1-2군의 음성대조군과 제1-3군 내지 제1-5군 사이의 유의차는 # p<0.05, ## p<0.01Significant differences between the normal control group of group 1-1 and group 1-2 to group 1-5 were * p<0.05, ** p<0.01, *** p<0.001; Significant differences between the negative control group 1-2 and groups 1-3 to 1-5 were # p<0.05, ## p<0.01
제1-1군의 정상대조군에 비하여 제1-2군의 음성대조군의 절대 및 상대 비장 중량은 모두 증가되는 양상으로 나타났으나, 제1-3군 및 제1-4군의 시험물질 투여군 중에서 제1-2군 대비 통계적으로 유의한 비장 무게 감소를 나타내지 않았다. Compared to the normal control group of group 1-1, the absolute and relative spleen weight of the negative control group of group 1-2 was both increased, but among the test substance administration groups of group 1-3 and group 1-4, There was no statistically significant reduction in spleen weight compared to group 1-2.
그러나 제1-5군의 덱사메타손 투여군의 경우, 비장 절대중량 및 상대중량수준 모두 제1-1군 및 제1-2군에 비하여 유의하게 낮았으며(p<0.001 및 p<0.01), 절대 중량의 경우 제1-2군 대비 약 25 % 수준에 불과한 것으로 나타나 덱사메타손에 의한 강력한 면역억제 효과가 비장의 축소로 이어진 것을 확인할 수 있었다.However, in the case of the dexamethasone-administered group of group 1-5, both absolute and relative weight levels of the spleen were significantly lower than those of groups 1-1 and 1-2 (p<0.001 and p<0.01), and In the case, it was found to be only about 25% of the level compared to group 1-2, indicating that the strong immunosuppressive effect of dexamethasone led to the contraction of the spleen.
5. 전체 백혈구, 호중구, 호산구 및 IgE 측정 결과5. Total leukocyte, neutrophil, eosinophil and IgE measurement results
아토피 피부염 유발 개시 49 일차의 부검일에 채취한 혈액을 이용하여, 자동세포수 계산기(TC20 Automated Cell Counter, Bio rad)로 전체 백혈구수를 측정하고, 플로우 사이토메트리(flow cytometry)로 호중구 및 호산구를 측정하며, ELISA 분석법으로 혈중 IgE 농도를 측정하여 표 5에 나타내었다.Using the blood collected on the day of necropsy on the 49th day of the initiation of atopic dermatitis, the total white blood cell count was measured with an automatic cell count calculator (TC20 Automated Cell Counter, Biorad), and neutrophils and eosinophils were measured by flow cytometry. Was measured, and the IgE concentration in blood was measured by ELISA assay, and is shown in Table 5.
(ㅧ103 세포/㎕)Whole white blood cells
(X10 3 cells/µl)
(ㅧ103 세포/㎕)Neutrophil
(X10 3 cells/µl)
(ㅧ102 세포/㎕)Eosinophil
(ㅧ10 2 cells/µl)
(㎍/㎖)IgE
(㎍/mL)
제1-1군의 정상대조군과 제1-2군 내지 제1-5군 사이의 유의차는 * p<0.05, ** p<0.01, *** p<0.001; 제1-2군의 음성대조군과 제1-3군 내지 제1-5군 사이의 유의차는 # p<0.05, ## p<0.01Significant differences between the normal control group of group 1-1 and group 1-2 to group 1-5 were * p<0.05, ** p<0.01, *** p<0.001; Significant differences between the negative control group 1-2 and groups 1-3 to 1-5 were # p<0.05, ## p<0.01
전체 백혈구수를 측정한 결과, 제1-3군의 자주천인국 착즙액 투여군 및 제1-5군의 덱사메타손 투여군에서만 제1-2군의 음성대조군에 비하여 전체 백혈구 수준이 유의하게 낮게 나타났다(p<0.05 및 p<0.01). As a result of measuring the total number of white blood cells, only in the group 1-3 administered with the juice solution of Soojungin-guk and the group 1-5 administered with dexamethasone, the level of total white blood cells was significantly lower than in the negative control group in group 1-2 (p< 0.05 and p<0.01).
호중구의 경우, 제1-2군의 음성대조군 및 제1-4군의 다래추출물 투여군은 제1-1군의 양성대조군에 비하여 유의하게 높았으며(p<0.001 및 p<0.05), 제1-3군의 자주천인국 착즙액 투여군 및 제1-5군의 덱사메타손 투여군은 제1-2군의 음성대조군에 비하여 유의하게 낮았다(p<0.01 및 p<0.05). In the case of neutrophils, the negative control group of group 1-2 and the group 1-4 treated with stalk extract were significantly higher than that of the positive control group of group 1-1 (p<0.001 and p<0.05). In group 3, the group administered with the juice solution of Jagalcheonin-guk and the group administered with dexamethasone in groups 1-5 were significantly lower than those in the negative control group in group 1-2 (p<0.01 and p<0.05).
또한 호산구의 경우, 제1-2군의 음성대조군 및 제1-4군의 다래추출물 투여군은 제1-1군의 양성대조군에 비하여 유의하게 높았으나(p<0.001 및 p<0.01), 제1-3군의 자주천인국 착즙액 투여군 및 제1-5군의 덱사메타손 투여군은 제1-2군의 음성대조군에 비하여 유의하게 낮았다(p<0.001 및 p<0.001). In addition, in the case of eosinophils, the negative control group 1-2 and the group 1-4 administration group were significantly higher than the positive control group 1-1 (p<0.001 and p<0.01). -The group 3 administered with the juice of Jinghui Cheonin Guk and the group 1-5 administered with dexamethasone were significantly lower than those of the negative control group 1-2 (p<0.001 and p<0.001).
제1-3군의 자주천인국 착즙액 투여군은 아토피 피부염의 병리기전에서 중요한 역할을 하는 호중구와 호산구 모두를 유의하게 감소시켰으며, 특히 양성대조군 1인 제1-4군의 다래추출물 투여군보다 현저히 우수하고, 양성대조군 2인 제1-5군의 덱사메타손 투여군과 유사한 수준으로 확인되었다.The group 1-3 administered with the extract of Jajucheonin-guk significantly reduced both neutrophils and eosinophils, which play an important role in the pathologic mechanism of atopic dermatitis, and was particularly superior to the group 1-4 treated with styrofoam extract. And, it was confirmed to be at a similar level to the dexamethasone-administered group of groups 1-5 of the positive control group 2.
한편 혈중 IgE 농도는, 제1-5군을 제외한 모든 아토피 유발군에서 제1-1군의 정상대조군에 비하여 유의하게 높았으나(p<0.001), 제1-3군의 자주천인국 착즙액 투여군 및 제1-5군의 덱사메타손 투여군은 제1-2군의 음성대조군에 비하여 유의하게 낮았다(p<0.001 및 p<0.001). 상기 결과로부터 제1-3군의 자주천인국 착즙액은 알레르기 반응의 핵심인자인 IgE 생성 억제에 매우 효과적인 것으로 확인되었다. On the other hand, blood IgE concentration was significantly higher in all atopy-inducing groups except for groups 1-5 than in the normal control group of group 1-1 (p<0.001), but the group 1-3 group administered the juice and The dexamethasone administration group of group 1-5 was significantly lower than that of the negative control group of group 1-2 (p<0.001 and p<0.001). From the above results, it was confirmed that the juice of Jajucheonin-guk of Group 1-3 is very effective in inhibiting the production of IgE, a key factor in allergic reactions.
실험예 2Experimental Example 2
1. 실험동물 및 시료의 준비1. Preparation of experimental animals and samples
자주천인국 착즙액과 자주천인국 추출물의 아토피 피부염 치료 효과, 및 자주천인국 착즙액의 투여 경로에 따른 아토피 피부염 치료 효과를 비교하기 위하여 추가 실험을 실시하였다. An additional experiment was conducted to compare the treatment effect of Jajucheonin-guk juice and Jajucheonin-guk extract on atopic dermatitis according to the administration route of Jajucheonin-guk juice.
실험예 1과 동일한 자주천인국 착즙액(EPJ) 분말을 사용하였다. 자주천인국 물 추출물(EPE)은 자주천인국(Echinacea purpurea) 전초의 건조물을 100 ℃의 물로 추출하여 얻은 추출물을 사용하였다. 자주천인국 물 추출물(EPE)의 고형분 함량은 4.9 중량%이었다. 실험예 1과 동일하게 '덱사메타손정(DEX)'을 구입하여 경구투여용 양성대조군(양성대조군 2)으로 사용하였다. 경피투여용 양성대조군(양성대조군 3)으로 '프로토픽연고 0.1 %(타크로리무스수화물)'를 구입하여 사용하였다. 상기 프로토픽연고 0.1 %는 백색 내지 미황색의 연고로 타크로리무스수화물이 1.02 mg/g 함유되어 있다.The same powder as in Experimental Example 1 was used. As for the water extract (EPE), the extract obtained by extracting the dried product of Echinacea purpurea outpost with water at 100°C was used. The solid content of the water extract (EPE) was 4.9% by weight. In the same manner as in Experimental Example 1,'dexamethasone tablet (DEX)' was purchased and used as a positive control (positive control 2) for oral administration. 'Protopic ointment 0.1% (tacrolimus hydrate)' was purchased and used as a positive control for transdermal administration (positive control 3). 0.1% of the protopic ointment is a white to pale yellow ointment containing 1.02 mg/g of tacrolimus hydrate.
실험동물, 사육조건 및 아토피 피부염 유발 방법은 모두 실험예 1과 동일하게 진행하였다. 다만 시험물질 투여 개시 이후 아토피 피부염을 지속적으로 유발하기 위해 15, 19, 22, 26, 29, 33, 36 및 40 일차까지 총 8회 아토피 피부염 유발시약을 귓바퀴, 경배부 및 앞다리 위치의 등 부위에 균일하게 도포하고, 42 일차에 부검을 실시하였다. 아래 표 6과 같이 이들 중 1군은 아토피 피부염을 유발시키지 않은 정상대조군, 나머지 6군에 대해서는 2주간 아토피 피부염을 유발시킨 후, 시험물질 투여를 개시하고 5주간 계속 아토피 피부염을 유발하면서 제2-3군은 부형제를 제외한 착즙액 고형분을 기준으로 200 mg/kg 경구 투여하고, 제2-4군은 추출물 고형분을 기준으로 200 mg/kg 경구 투여하며, 제2-5군은 '덱사메타손' 유효성분을 기준으로 2 mg/kg을 10 mL/kg 투여 액량을 기준으로 1일 1회 경구 투여하였다. 정상대조군 및 음성대조군은 비히클로 생리식염수를 10 mL/kg 경구 투여하였다.Experimental animals, breeding conditions, and methods of inducing atopic dermatitis were all performed in the same manner as in Experimental Example 1. However, in order to continuously induce atopic dermatitis after the start of administration of the test substance, atopic dermatitis-inducing reagent was applied to the back of the auricle, neck and forelimbs for a total of 8 times until day 15, 19, 22, 26, 29, 33, 36 and 40. It was applied uniformly, and an autopsy was performed on the 42nd day. As shown in Table 6 below, group 1 of them induces atopic dermatitis for 2 weeks in the normal control group, and the other 6 groups induce atopic dermatitis for 2 weeks. Group 3 is administered 200 mg/kg orally based on the solid content of the juice extract excluding excipients, Group 2-4 is administered orally 200 mg/kg based on the solid content of the extract, and Group 2-5 is the active ingredient of'dexamethasone'. 2 mg/kg was administered orally once a day based on a 10 mL/kg dose. The normal control group and the negative control group were orally administered 10 mL/kg of physiological saline as a vehicle.
또한 제2-6군은 부형제를 제외한 착즙액 고형분을 기준으로 200 mg/kg을 10 mL/kg/day로 아토피가 유발된 등 부위에 경피 투여하고, 제2-7군은 프로토픽연고 0.1 %를 100 mg/마리/day로 경피 투여하였다.In addition, groups 2-6 were transdermally administered 200 mg/kg to the atopy-induced back area at 10 mL/kg/day based on the solid content of the juice extract excluding excipients, and group 2-7 was administered 0.1% Protopic Ointment. It was administered transdermally at 100 mg/mari/day.
2. 혈액 내 림프구, 호산구 및 호염구 비율 측정 결과2. Results of measuring the ratio of lymphocytes, eosinophils and basophils in the blood
아토피 피부염 유발 개시 42 일차의 부검일에 채취한 혈액을 이용하여 백혈구의 비율을 확인하였다. 채혈한 혈액 중 일부를 항응고제인 EDTA-2K가 들어있는 CBC bottle에 주입한 후 자동혈액분석기(ADVIA 2120, SIEMENS, USA)를 이용하여 림프구(Lymphocyte), 호산구(Eosinophil) 및 호염구(Basophil)의 비율을 확인하여 표 7에 나타내었다.The percentage of leukocytes was confirmed using the blood collected on the day 42 of necropsy on the 42nd day of induction of atopic dermatitis. The ratio of lymphocytes, eosinophils and basophils using an automatic blood analyzer (ADVIA 2120, SIEMENS, USA) after injecting some of the collected blood into a CBC bottle containing an anticoagulant EDTA-2K It is shown in Table 7 to confirm.
제2-1군의 정상대조군과 제2-2군 내지 제2-7군 사이의 유의차는 * p<0.05, ** p<0.01; 제2-2군의 음성대조군과 제2-3군 내지 제2-7군 사이의 유의차는 # p<0.05, ## p<0.01, ### p<0.001Significant differences between the normal control group of group 2-1 and groups 2-2 to 2-7 were * p<0.05, ** p<0.01; Significant differences between the negative control group 2-2 and groups 2-3 to 2-7 were # p<0.05, ## p<0.01, ### p<0.001
림프구의 비율은 제2-5군의 양성대조군 2의 경구 투여군 및 제2-3군의 자주천인국 착즙액(EPJ) 경구 투여군에서만 유의적으로 낮게 나타났다(p<0.01 및 p<0.05). 한편 제2-4군의 자주천인국 물 추출물(EPE) 경구 투여군에서는 유의적인 차이를 나타내지 않았고, 또한 제2-7군의 자주천인국 착즙액(EPJ) 경피 투여군에서도 유의적인 차이를 나타내지 않았다.The ratio of lymphocytes was significantly lower only in the oral administration group of positive control group 2 of group 2-5 and the oral administration group of JJV extract (EPJ) of group 2-3 (p<0.01 and p<0.05). On the other hand, there was no significant difference in the oral administration group of Jagalcheoninguk water extract (EPE) of group 2-4, and also did not show a significant difference in the transdermal administration group of Jagalcheoninguk juice (EPJ) of group 2-7.
아토피 피부염에서 염증 관련 세포수, 특히 호산구의 비율이 증대되고, 호산구는 아토피 피부염의 병리기전에 중요한 역할을 하는 것으로 알려져 있다. 호산구의 비율은 제2-1군의 정상대조군의 경구 투여군에 비해서 제2-2군의 음성대조군의 경구 투여군에서 유의적으로 현저히 증가하였고(p<0.01), 제2-3군 내지 제2-7군에서 제2-2군의 음성대조군에 비해 유의적으로 감소하였다(p<0.01, p<0.001), In atopic dermatitis, the number of inflammation-related cells, in particular, the ratio of eosinophils is increased, and eosinophils are known to play an important role in the pathological mechanisms of atopic dermatitis. The proportion of eosinophils was significantly increased in the oral administration group of the negative control group 2-2 compared to the oral administration group of the normal control group 2-1 (p<0.01), and in groups 2-3 to 2 It was significantly decreased in group 7 compared to the negative control group of group 2-2 (p<0.01, p<0.001),
그 중에서도 제2-3군의 자주천인국 착즙액(EPJ) 경구 투여군은 제2-4군의 자주천인국 물 추출물(EPE) 경구 투여군, 제2-7군의 자주천인국 착즙액(EPJ) 경피 투여군은 물론 제2-5군의 양성대조군 2 및 제2-7군의 양성대조군 3에 비해서도 호산구 비율을 더욱 현저히 감소시켰다(p<0.001).Among them, the oral administration group of Epjeong-in-guk juice (EPJ) of group 2-3 was the oral administration group of EPE-dosed water extract (EPE) of group 2-4, and the transdermal administration of EPJ of group 2-7 Of course, compared to the positive control group 2 of group 2-5 and the positive control group 3 of group 2-7, the proportion of eosinophils was significantly reduced (p<0.001).
호염구의 비율은 각 군들 사이에 유의적인 차이를 나타내지 않았으나, 제2-3군의 자주천인국 착즙액(EPJ) 경구 투여군, 제2-5군의 양성대조군 2 및 제2-7군의 양성대조군 3에서 다른 군들에 비해 상대적으로 낮은 비율로 나타났다.The proportion of basophils did not show any significant difference between the groups, but the oral administration group of JJV (EPJ) in group 2-3, positive control group 2 in group 2-5, and positive control group 3 in group 2-7. Showed a relatively low ratio compared to other groups.
따라서 자주천인국 착즙액은 경구 투여시 자주천인국 물 추출물에 비해 림프구 및 호산구의 비율을 유의적으로 감소시키고, 또한 자주천인국은 경피 투여하는 것보다 경구 투여하는 것이 림프구 및 호산구의 비율을 유의적으로 감소시키는데 더욱 효과적임을 확인할 수 있었다.Therefore, when administered orally, the ratio of lymphocytes and eosinophils was significantly reduced when administered orally, and when administered orally, the ratio of lymphocytes and eosinophils was significantly reduced when administered orally. It was confirmed that it was more effective in ordering.
통계분석Statistical analysis
상기 실험예 1 및 실험예 2의 실험 결과는 평균±표준편차로 나타내고, 모수적인 다중비교의 경우, 자료의 정규성을 가정하고, 모수적 일원분산분석(One-way ANOVA)으로 검정하였으며, 그 결과가 유의할 경우, Dunnett's multiple comparison test를 이용하여 사후검정을 실시하여 시험군간 유의한 차이를 분석하였다. 비모수적인 다중비교의 경우, Kruskal-Wallis'H-test로 검정하여, 그 결과가 유의할 경우 사후분석인 Mann-Whitney U test를 이용하여 시험군간 유의한 차이를 분석하였다.The experimental results of Experimental Example 1 and Experimental Example 2 are expressed as mean ± standard deviation, and in the case of parametric multiple comparison, the normality of the data was assumed, and the result was tested by a parametric one-way variance analysis (One-way ANOVA). If is significant, a post-test was performed using Dunnett's multiple comparison test to analyze significant differences between test groups. In the case of nonparametric multiple comparisons, the test was performed with the Kruskal-Wallis'H-test, and if the result was significant, the significant difference between the test groups was analyzed using the post-analysis Mann-Whitney U test.
통계학적 분석은 Prism 7.04(GraphPad Software Inc., San Diego, CA, USA)을 이용하여 실시하였으며, p값이 0.05 미만일 경우, 통계학적으로 유의한 것으로 판정하였다. Statistical analysis was performed using Prism 7.04 (GraphPad Software Inc., San Diego, CA, USA), and a p value of less than 0.05 was determined to be statistically significant.
아래에 본 발명의 자주천인국 착즙액을 포함하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, an example of the formulation of a composition comprising the juice of the Jajucheonin-guk of the present invention is described, but the present invention is not intended to limit it, but is intended to be described in detail.
제제예 1: 산제의 제조Formulation Example 1: Preparation of powder
자주천인국 착즙액(EPJ) 분말 20 mgJuju Cheonin Guk Juice (EPJ) Powder 20 mg
유당 100 mg100 mg lactose
탈크 10 mg10 mg of talc
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2: 정제의 제조Formulation Example 2: Preparation of tablets
자주천인국 착즙액(EPJ) 분말 10 mgJuju Cheonin Guk Juice (EPJ) Powder 10 mg
옥수수전분 100 mg100 mg corn starch
유당 100 mg100 mg lactose
스테아린산 마그네슘 2 mg2 mg of magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above ingredients, tablets are prepared by tableting according to a conventional tablet preparation method.
제제예 3: 캡슐제의 제조Formulation Example 3: Preparation of Capsule
자주천인국 착즙액(EPJ) 분말 10 mgJuju Cheonin Guk Juice (EPJ) Powder 10 mg
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mg14.8 mg lactose
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare a capsule.
제제예 4: 과립제의 제조Formulation Example 4: Preparation of granules
자주천인국 착즙액(EPJ) 분말 1,000 mgJuju Cheonin Guk Juice (EPJ) Powder 1,000 mg
비타민 혼합물 적량Vitamin mixture right amount
비타민 A 아세테이트 70 ㎍Vitamin A acetate 70 ㎍
비타민 E 1.0 mg1.0 mg of vitamin E
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mgVitamin B2 0.15 mg
비타민 B6 0.5 mg0.5 mg of vitamin B6
비타민 B12 0.2 ㎍Vitamin B12 0.2 ㎍
비타민 C 10 mgVitamin C 10 mg
비오틴 10 ㎍Biotin 10 ㎍
니코틴산아미드 1.7 mg1.7 mg of nicotinic acid amide
엽산 50 ㎍Folic acid 50 ㎍
판토텐산 칼슘 0.5 mg0.5 mg of calcium pantothenate
무기질 혼합물 적량Suitable amount of inorganic mixture
황산제1철 1.75 mg1.75 mg ferrous sulfate
산화아연 0.82 mgZinc oxide 0.82 mg
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgDicalcium phosphate 55 mg
구연산칼륨 90 mg90 mg of potassium citrate
탄산칼슘 100 mg100 mg of calcium carbonate
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 건강기능식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강기능식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.As for the composition ratio of the vitamin and mineral mixture, ingredients suitable for health functional foods are mixed in a preferred embodiment, but the mixing ratio may be arbitrarily modified, and the above ingredients are mixed according to a general health functional food manufacturing method. Next, granules are prepared and can be used to prepare a health functional food composition according to a conventional method.
제제예 5: 음료 제형의 제조Formulation Example 5: Preparation of beverage formulation
자주천인국 착즙액(EPJ) 분말 1,000 mgJuju Cheonin Guk Juice (EPJ) Powder 1,000 mg
구연산 1,000 mg1,000 mg citric acid
올리고당 100 g100 g oligosaccharides
매실농축액 2 g2 g of plum concentrate
타우린 1 g1 g taurine
정제수를 가하여 전체 900 mLTotal 900 mL with purified water
통상의 음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 기능성 음료 조성물 제조에 사용한다. After mixing the above ingredients according to a conventional beverage manufacturing method, after stirring and heating at 85° C. for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and then stored in a refrigerator. It is used to prepare a functional beverage composition.
제제예 6: 사료 조성물의 제조Formulation Example 6: Preparation of feed composition
자주천인국 착즙액(EPJ) 분말 0.1 kg, 옥수수 25.5 kg, 소맥 15.04 kg, 소맥분 8.15 kg, 미강 7.4 kg, 대두박 18 kg, 옥구르텐 1 kg, 닭부산물 14 kg, 동물성유지 9 kg, 가공염 0.3 kg, 인산제삼칼슘 0.3 kg, 석회석 1 kg, 염화콜린 0.01 kg, 비타민 0.05 kg, 미네랄 0.05 kg 및 소화효소제 0.1 kg을 혼합하여 동물(개, 애완견) 사료 조성물을 제조하였다. JJU Cheonin Guk Juice (EPJ) powder 0.1 kg, corn 25.5 kg, wheat 15.04 kg, wheat flour 8.15 kg, rice bran 7.4 kg, soybean meal 18 kg, octane 1 kg, chicken by-products 14 kg, animal oil 9 kg, processed salt 0.3 kg , 0.3 kg of tricalcium phosphate, 1 kg of limestone, 0.01 kg of choline chloride, 0.05 kg of vitamins, 0.05 kg of minerals and 0.1 kg of digestive enzymes were mixed to prepare an animal (dog, dog) feed composition.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2020/004992 WO2020209702A1 (en) | 2019-04-12 | 2020-04-13 | Composition for ameliorating, treating, or preventing skin diseases comprising echinacea purpurea juice |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190042865 | 2019-04-12 | ||
KR20190042865 | 2019-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20200120550A true KR20200120550A (en) | 2020-10-21 |
Family
ID=73034860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200044163A KR20200120550A (en) | 2019-04-12 | 2020-04-10 | Composition for improving, preventing or treating skin disease comprising pressed juice of Echinacea purpurea |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20200120550A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230077327A (en) * | 2021-11-25 | 2023-06-01 | 주식회사 젠트리바이오 | Composition and manufacturing method for antioxidant and anti-inflammatory effects, mainly containing complexes of natural substance extracts |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101302222B1 (en) | 2012-09-18 | 2013-08-30 | 주식회사 아가방앤컴퍼니 | Mixed vegetable extracts for preventing, improving and treating atopic dermatitis and allergic skin diseases, composition including the same and method of producing the same |
KR20160128589A (en) | 2015-04-29 | 2016-11-08 | 스킨큐어(주) | A composition for improving inflammatory skin diseases containing natural extracts |
KR101891218B1 (en) | 2018-01-22 | 2018-08-23 | 주식회사 위드내추럴 | Composition for treatment of dermatitis comprising natural plant extracts |
-
2020
- 2020-04-10 KR KR1020200044163A patent/KR20200120550A/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101302222B1 (en) | 2012-09-18 | 2013-08-30 | 주식회사 아가방앤컴퍼니 | Mixed vegetable extracts for preventing, improving and treating atopic dermatitis and allergic skin diseases, composition including the same and method of producing the same |
KR20160128589A (en) | 2015-04-29 | 2016-11-08 | 스킨큐어(주) | A composition for improving inflammatory skin diseases containing natural extracts |
KR101891218B1 (en) | 2018-01-22 | 2018-08-23 | 주식회사 위드내추럴 | Composition for treatment of dermatitis comprising natural plant extracts |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230077327A (en) * | 2021-11-25 | 2023-06-01 | 주식회사 젠트리바이오 | Composition and manufacturing method for antioxidant and anti-inflammatory effects, mainly containing complexes of natural substance extracts |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20100127420A (en) | Composition for improving bioavailability of saponin | |
KR20200120550A (en) | Composition for improving, preventing or treating skin disease comprising pressed juice of Echinacea purpurea | |
KR20210053784A (en) | A composition for the prevention or treatment of depression, stress or memory malfunctions containing Rosa multiflora Fructus extract | |
KR102252268B1 (en) | Preparation manufacturing of composition for the improving of respiratory disease comprising pear and citron, and composition prepared thereby | |
KR20210050475A (en) | Composition for improving muscle function comprising ginsenoside Rf, ginsenoside composition comprising gincenoside Rf, or mixture thereof as an effective component | |
KR20060102621A (en) | Composition containing sanguisorba officinalis extract for treatment hypersensitive skin disease | |
KR20130077317A (en) | Functional food composition for improving skin condition and preparation method thereof | |
KR100670850B1 (en) | Composition containing Gentianae Macrophyllae Radix Extract for treatment hypersensitive skin disease | |
KR102450143B1 (en) | Composition for improving, preventing or treating skin disease comprising Thymus plant extract | |
KR102156543B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising Rosa davurica extract as effective component | |
KR20190009589A (en) | Composition comprising bee venom isolated from Vespa mandarinia worker for prevention or treating avian influenza | |
KR102510297B1 (en) | A composition for the prevention or treatment of depression, stress or memory malfunctions containing Erythronium japonicum extract | |
US11547735B2 (en) | Composition for ameliorating psoriasis symptoms containing extract of Thalictrum squarrosum steph | |
KR20150083327A (en) | Composition comprising an extract or a fraction of Euonymus alatus for preventing or treating asthma | |
WO2020209702A1 (en) | Composition for ameliorating, treating, or preventing skin diseases comprising echinacea purpurea juice | |
US11648284B2 (en) | Composition for ameliorating psoriasis symptoms containing extract of Sphallerocarpus gracilis | |
KR102634302B1 (en) | Composition for preventing or treating cognitive impairment comprising extract of iris lactea | |
KR20230096583A (en) | A composition for the prevention or treatment of pain containin Plantago asiatica L extract | |
KR102485676B1 (en) | A composition for improving, preventing and treating of obesity comprising Ulva pertusa Kjellman extracts | |
KR101711397B1 (en) | Pharmaceutical compositions and health functional foods comprising Persicaria fauriei extracts for preventing or treating anticancer agent-induced of hematopoietic toxicity | |
KR20120136460A (en) | A pharmaceutical comprising the extract of ixeris dentata nakai for treating or preventing skin disease | |
KR20230134448A (en) | Composition for improvement of respiratory health containing complex extracts of Humulus japonicus as an active ingredient | |
US20220080013A1 (en) | Composition for ameliorating psoriasis symptoms containing extract of dianthus superbus l. | |
KR102249706B1 (en) | Composition for life extension containing ginseng fruit extract | |
KR20230041255A (en) | Composition for improving psoriasis symptom comprising extract of Aruncus dioicus var. kamtschaticus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X601 | Decision of rejection after re-examination |